Position in SPRY
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$3,388,965
-$158,112 QoQ
Shares Held
422,038
+19.6% QoQ
Ownership
0.425%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
3 quarters on record
Voting authority
Sole 11%
Shared 0%
None 89%
Common Shares in SPRY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026FIRST TRUST ADVISORS LP holds $2,375,392,616 across 80 Biotechnology names. SPRY ranks #53 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
346,855 | $267,994,047 | |
| 2 | INCY |
Incyte Corp
|
1,500,792 | $141,254,543 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
306,461 | $136,847,094 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
382,701 | $126,624,279 | |
| 5 | MRNA |
Moderna, Inc.
|
2,392,693 | $121,548,804 | |
| 6 | EXEL |
Exelixis, Inc.
|
2,534,992 | $108,725,806 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
577,479 | $97,605,500 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
1,482,340 | $95,803,634 |
All Filings in SPRY
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,388,965 | 422,038 | Shares | Sole | 2026-05-13 | |
| 2025-09-30 | $3,547,077 | 352,943 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $5,935,076 | 340,119 | Shares | Sole | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||